Showing 2751-2760 of 5617 results for "".
- In Patients with NAFLD, Type 2 Diabetes Significantly Ups Risk for Hepatic Decompensation, Hepatocellular Carcinomahttps://reachmd.com/news/in-patients-with-nafld-type-2-diabetes-significantly-ups-risk-for-hepatic-decompensation-hepatocellular-carcinoma/2451795/In individuals with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), the risk of hepatic decompensation and hepatocellular carcinoma (HCC) at 5 years was more than 3-fold greater than among those without T2D, according to new data from an int
- Aflibercept 8 mg Sustains 96-Week Outcomes in PULSAR nAMD Trialhttps://reachmd.com/news/aflibercept-8-mg-sustains-96-week-outcomes-in-pulsar-namd-trial/2487292/Key Takeaways Week 96 visual and anatomic outcomes were maintained, and BCVA differences versus 2q8 met the noninferiority criteria specified for the primary end point at week 48. Extended intervals were common with aflibercept 8 mg among patients comp
- GLP-1 Receptor Agonists and Suicide Risk in a Nationwide Studyhttps://reachmd.com/news/glp-1-receptor-agonists-and-suicide-risk-in-a-nationwide-study/2487050/Key Takeaways In these Danish cohorts, GLP-1 receptor agonist initiation was not linked to a higher adjusted hazard versus SGLT-2 inhibitors after 1 year of follow-up and was associated with a lower adjusted hazard versus DPP-4 inhibitors. Within-perso
- Phase 3 Brilliance Studies Begin for Alixorexton in Narcolepsyhttps://reachmd.com/news/phase-3-brilliance-alixorexton-narcolepsy/2486600/Alkermes has initiated the Brilliance phase 3 program to evaluate oral
- Nail Psoriasis and Real-World Data Highlight Tildrakizumab’s Staying Powerhttps://reachmd.com/news/nail-psoriasis-and-real-world-data-highlight-tildrakizumabs-staying-power/2486482/Two posters presented at the American Academy of Dermatology (AAD) Annual Meeting highlight both clinical trial efficacy and real-world durability of tildrakizumab, an interleukin (IL)-23 p19 inhibitor, in patients with moderate-to-severe plaque psoriasis.
- Benralizumab Reduces Flare Risk in Hypereosinophilic Syndrome: Results from the Phase 3 NATRON Trialhttps://reachmd.com/news/phase-3-natron-trial-benralizumab-reduces-flares-in-fip1l1pdgfranegative-hes/2486467/
- National Survey Findings on Obesity Prevalence in High School Studentshttps://reachmd.com/news/survey-obesity-prevalence-high-school/2486310/New Youth Risk Behavior Survey (YRBS) findings show that obesity prevalence among US high school students (grades 9–12) rose
- GE HealthCare’s View Receives FDA 510(k): Cloud‑Native Diagnostic Viewer with Embedded AIhttps://reachmd.com/news/ge-healthcares-view-receives-fda-510k-cloudnative-diagnostic-viewer-with-embedded-ai/2485988/GE HealthCare announced U.S. FDA 510(k) clearance for View; in
- Preclinical Nasal Spray Boosts Mucosal Defense and Blocks Allergic Responses in Micehttps://reachmd.com/news/preclinical-nasal-spray-boosts-mucosal-defense-and-blocks-allergic-responses-in-mice/2485812/An intranasal formulation described as GLA-3M-052-LS+OVA was reported in a Stanford Medicine mouse study to “supercharge” airway and mucosal defenses, with the write-up describing bro
- Most Nations Off Track to Meet 2030 Skin NTD SDG Targets: Reporthttps://reachmd.com/news/most-nations-off-track-to-meet-2030-skin-ntd-sdg-targets-report/2485823/A new report in JAMA Dermatology revealed that most countries are unlikely to achieve the World Health Organization (WHO) target of a 75% reduction in disability-adjusted life-years (DALYs) from skin-related neglected tropical diseases (NTDs) from 2020 lev